Last Updated on June 4, 2024 by The Health Master
Cancer
Cancer Treatment and You: This article contains vital information for patients with gBRCA-mutated advanced ovarian cancer who have undergone multiple chemotherapy treatments.
The Drug Controller General of India (DCGI), the country’s highest drug regulatory authority, has issued a crucial update regarding the use of Olaparib tablets, an anti-cancer medication manufactured by AstraZeneca.
Limited Use of Olaparib for Specific Cases
The DCGI has directed state drug regulators to restrict the marketing of Olaparib (100mg and 150mg tablets) for the treatment of advanced ovarian cancer patients with a gBRCA mutation who have received three or more prior chemotherapy regimens.
This decision stems from concerns about potential adverse effects associated with this specific use case.
Patient Safety First:
Reason for Restriction:
Recent data analysis (post hoc subgroup analysis) revealed a potential negative impact on overall survival for patients taking Olaparib compared to those receiving standard chemotherapy after undergoing three or more prior chemotherapy treatments.
Expert Review:
The DCGI, in collaboration with the Subject Expert Committee (SEC) on Oncology, meticulously reviewed the available evidence during meetings held on March 19th and 20th, 2024.
Clinical Data Provided:
AstraZeneca Pharma India Limited submitted clinical data supporting the withdrawal of this particular use case for Olaparib tablets.
What This Means for Patients:
Continued Use for Other Indications:
Thankfully, Olaparib remains approved for treating other types of cancers and advanced ovarian cancer cases that fall outside the restricted category.
Consulting Your Doctor:
If you have undergone three or more prior chemotherapy treatments for gBRCA-mutated advanced ovarian cancer, it’s crucial to consult your doctor immediately to discuss alternative treatment options.
Previous Approval History:
For clarity, it’s important to note that the DCGI initially approved 100mg and 150mg Olaparib tablets on August 13, 2018.
This approval covered the treatment of adult patients with specific forms of breast cancer and ovarian cancer.
Staying Informed:
This update highlights the DCGI’s commitment to patient safety by constantly monitoring the effectiveness and safety of medications.
We recommend discussing any concerns you may have with your doctor and staying informed about developments in your specific cancer treatment plan.
Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.
DCGI to SLAs: Cancel this Antibiotic Drug Combination
DCGI to Collaborate with Stakeholders: Empowering Ease of Doing Business
DCGI issues Guidelines on Sampling of Drugs
DCGI to Blood Centres: Comply with revised guidelines for recovery of processing charges
USFDA approval granted for Asthma Treatment Drug
USFDA inspection concluded at Solara Pharma without any observations
NPPA revised Ceiling price of 1 scheduled formulation: May 2024
FSSAI: Food Labelling and Display – Chapter-6
Indian Regulators Crack Down on Unapproved Antibiotics to Fight Misuse
CDSCO Committee to Revise Rule 64 for drug sales in India
One Nation-One Pharmacist Registration to Boost Recognition of Pharmacy Professionals
USFDA issued Form 483 with 6 observations to Lupin
Gujarat FDCA and IDMA Join Forces for GMP Compliance Training
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
